公开(公告)号：US20240366599A1

公开(公告)日：2024-11-07

申请号：US18646893

申请日：2024-04-26

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Angela TALLEY ,  David MELNICK

IPC: A61K31/506 ,  A61K31/133 ,  A61K31/438 ,  A61K31/496 ,  A61K31/7048 ,  A61K31/7052 ,  A61P31/04

Abstract: The present disclose provides methods of treating NTM-PD and other bacterial infections, including pulmonary tuberculous and nontuberculous mycobacteria infections. Clinical studies have established the safety of SPR720 up to daily oral dosages of 2000 mg and shown that once daily oral dosing is sufficient to provide efficacious plasma levels of the active agent, SPR719. Clinical studies have also shown that there is no significant food effect for SPR720 and that the drug may be given in to a patient in the fed or fasted state. Clinical studies have also established that SPR720 can be administered safely to elderly patients. The present disclosure provides a method of treating a bacterial infection in a patient comprising administering a daily oral dose of SPR720, or a pharmaceutically acceptable salt thereof, the oral dose comprising 100 mg SPR720 to 1500 mg SPR720.

公开(公告)号：US20230322858A1

公开(公告)日：2023-10-12

申请号：US18126270

申请日：2023-03-24

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Pamela BROWN ,  Michael DAWSON ,  Mona SIMONOVIC ,  Steven BOAKES ,  Esther DUPERCHY ,  Steven James STANWAY ,  Antoinette WILSON ,  Stephen Frederick MOSS

IPC: C07K7/62 ,  A61K38/00

CPC classification number: C07K7/62 ,  A61K38/00 ,  Y02A50/30

Abstract: Provided are compounds of formula (III), and the use of compounds of formula (III) in methods of treatment, such as methods of treating a microbial infection. The compounds of formula (III) is: where —R15 is an amino-containing group: and —R1, —R2, —R3, —R4, —R8, —RA, Q, —R16, —R17 are as described in further detail in the description.

公开(公告)号：US20220142986A1

公开(公告)日：2022-05-12

申请号：US17525619

申请日：2021-11-12

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Akash JAIN ,  Ching-Kuo Jim CHOW

IPC: A61K31/427 ,  A61K9/20 ,  A61P31/04

Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

公开(公告)号：US20210221848A1

公开(公告)日：2021-07-22

申请号：US17157393

申请日：2021-01-25

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Pamela BROWN ,  Michael DAWSON ,  Mona SIMONOVIC ,  Steven BOAKES ,  Esther DUPERCHY ,  Steven James STANWAY ,  Antoinette WILSON ,  Stephen Frederick MOSS

IPC: C07K7/62 ,  A61K38/00

Abstract: Provided are compounds of formula (III), and the use of compounds of formula (III) in methods of treatment, such as methods of treating a microbial infection. The compounds of formula (III) is: where —R15 is an amino-containing group: and —R1, —R2, —R3, —R4, —R, —RA, Q, —R16, —R17 are as described in further detail in the description.

公开(公告)号：US20210122753A1

公开(公告)日：2021-04-29

申请号：US17136759

申请日：2020-12-29

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Akash JAIN ,  Evan HECKER ,  Richard EDWARDS ,  Thierry BONNAUD

IPC: C07D477/20

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

公开(公告)号：US20250051334A1

公开(公告)日：2025-02-13

申请号：US18823147

申请日：2024-09-03

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Akash JAIN ,  Evan HECKER ,  Richard EDWARDS ,  Thierry BONNAUD

IPC: C07D477/20 ,  A61K45/06

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

公开(公告)号：US20250049766A1

公开(公告)日：2025-02-13

申请号：US18665330

申请日：2024-05-15

Applicant: Spero Therapeutics, Inc.

Inventor： Akash Jain ,  Ching-Kuo Jim Chow

IPC: A61K31/427 ,  A61K9/20 ,  A61P31/04

Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

公开(公告)号：US20230331728A1

公开(公告)日：2023-10-19

申请号：US18332566

申请日：2023-06-09

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Akash JAIN ,  Evan HECKER ,  Richard EDWARDS ,  Thierry BONNAUD

IPC: C07D477/20

CPC classification number: C07D477/20 ,  A61K45/06

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

公开(公告)号：US11718621B2

公开(公告)日：2023-08-08

申请号：US17136759

申请日：2020-12-29

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Akash Jain ,  Evan Hecker ,  Richard Edwards ,  Thierry Bonnaud

IPC: C07D477/20 ,  A61K45/06 ,  A61P31/04

CPC classification number: C07D477/20 ,  A61K45/06 ,  C07B2200/13

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

公开(公告)号：US11459357B2

公开(公告)日：2022-10-04

申请号：US17253426

申请日：2019-06-25

Applicant: SPERO THERAPEUTICS, INC.

Inventor： Pamela Brown ,  Michael Dawson ,  Mona Simonovic ,  Steven Boakes ,  Esther Duperchy ,  Dean Rivers ,  Roy Lester ,  Scott Coleman

IPC: A61K38/12 ,  C07K7/62 ,  A61K38/00

Abstract: The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: wherein —R15 is a group: and —R16 is hydrogen; —R17 is hydrogen -L- is a covalent bond or methylene; and —Ar is optionally substituted aryl. The groups —X—, —R1, —R2, —R3, —R4, and —R8 are as defined herein.